Knowledge Base

Why death is not an AE?

7 December 2023
2 min read

Death is not an AE because it is a final outcome of the patient's condition, rather than an adverse event itself. An adverse event (AE) in clinical trials refers to any untoward medical occurrence in a patient or group of patients treated with a drug or other intervention. AEs can include symptoms such as nausea, vomiting, diarrhea, headache, dizziness, and abdominal pain. Three examples of AEs that can cause death are:
Fatal arrhythmias - abnormal heart rhythms that can lead to sudden cardiac arrest and death if left untreated.
Acute respiratory distress syndrome (ARDS) - a severe lung condition that can cause breathing difficulties and respiratory failure, leading to death in some cases.
Severe allergic reactions (anaphylaxis) - a life-threatening reaction that occurs when the immune system overreacts to an allergen, causing swelling of the airways, difficulty breathing, and in severe cases, death.

Decoding Durvalumab: a comprehensive study of its R&D trends and its clinical results in 2023 AACR
Decoding Durvalumab: a comprehensive study of its R&D trends and its clinical results in 2023 AACR
7 December 2023
Recent results presented at the AACR Congress show the benefit of durvalumab with chemotherapy, then as an adjuvant, in resectable NSCLC patients, confirming immunotherapy's effectiveness in both neoadjuvant and adjuvant stages.
Read →
What is the EU Drug Regulatory System?
"What" Series
2 min read
What is the EU Drug Regulatory System?
7 December 2023
The European medicines regulatory system is based on a network of around 50 regulatory authorities from the 30 EEA countries (27 EU Member States plus Iceland, Liechtenstein and Norway), the European Commission and EMA.
Read →
Aldeyra Therapeutics Gets Full Feedback Note from U.S. FDA on New Eye Dryness Medication Submission, Reproxalap
Latest Hotspot
4 min read
Aldeyra Therapeutics Gets Full Feedback Note from U.S. FDA on New Eye Dryness Medication Submission, Reproxalap
7 December 2023
Aldeyra Therapeutics, Inc. has disclosed that it has received a Complete Response Letter from the FDA regarding the New Drug Application of reproxalap.
Read →
What is dose expansion and why is a dose expansion trial performed?
"What" Series
2 min read
What is dose expansion and why is a dose expansion trial performed?
7 December 2023
Dose expansion trials are clinical trials that evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of a new drug or treatment in a larger group of patients than in the initial dose escalation trial.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.